Tuesday saw bumps in Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), and other vaccine producers as worries about rising COVID-19 and flu infections in the United States drove demand for immunization-oriented businesses to continue growing.

Moderna rose 11%; Novavax and others, including Inovio Pharmaceuticals (INO), CureVac (NASDAQ:CVAC), and Arcturus Therapeutics (NASDAQ:ARCT), also traded significantly higher. Manufacturers of the COVID-19 vaccination Comirnaty, Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), noted more meager increases.

Warning! GuruFocus has detected 6 Warning Signs with MRNA.

Based on last week's U.S. Centers for Disease Control and Prevention (CDC) data showing increasing COVID-19 activity in most areas and a concurrent rise in seasonal flu, especially among small children, the rally followed last week's Citing their success in lowering serious disease and hospitalization, the CDC advised Americans to get recommended vaccinations.

The organization also underlined how common respiratory syncytial virus (RSV) is in young children. With its mREVIA medicine, Moderna has joined Pfizer's Abysvo and GSK's Arexvy vaccines on the RSV vaccination market. As health authorities stress preventative actions, the increasing need for vaccinations to treat certain respiratory diseases has attracted investment attention in the sector.

This article first appeared on GuruFocus.

View Comments